Answers are grounded in this paper and cite their sources.
Postoperative adjuvant immunotherapy (aIT) represents a strategy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with neoadjuvant chemoimmunotherapy (nCIT) followed by esophagectomy. This multicenter retrospective cohort enrolled 418 Chinese LA-ESCC patients treated with nCIT followed by esophagectomy, split into aIT and surveillance groups. We balanced baseline confounders via 1:1 propensity score matching (PSM) and analyzed overall survival (OS) and event-free survival (EFS). With a median 48.7-month follow-up, aIT was associated with higher 4-year OS among matched patients (78.21% vs. 65.20%, HR=0.571, p = 0.012), while EFS (64.45% vs. 59.46%, HR=0.735, p = 0.114) showed no intergroup difference. The observed OS association with aIT was limited to patients without major pathological response (non-MPR). In this retrospective cohort, postoperative aIT was associated with longer overall survival specifically among non-MPR LA-ESCC patients following nCIT.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: